US FDA is proposing checklists sponsors should use when filing a de novo application in a draft guidance that seeks to outline the minimum standards for a de novo submission to be accepted for review and timelines for FDA to assess acceptance criteria.
The draft guidance, "Acceptance Review for De Novo Classification Requests," is linked to new commitments the agency made in the MDUFA IV user-fee program, which took effect Oct. 1, for...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?